Thrombosis and Occlusion of Vascular Access in Hemodialyzed Patients

Martina Montagnana; Tiziana Meschi; Loris Borghi; Giuseppe Lippi

doi:10.1055/s-0031-1297373

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2011; 37(8): 946-954
DOI: 10.1055/s-0031-1297373

Thrombosis and Occlusion of Vascular Access in Hemodialyzed Patients

Martina Montagnana¹ , Tiziana Meschi² , Loris Borghi² , Giuseppe Lippi³

¹Sezione di Biochimica Clinica, Dipartimento di Scienze della Vita e della Riproduzione, Università degli Studi di Verona
²Sezione di Medicina Interna e Lungodegenza Critica, Dipartimento di Scienze Cliniche, Azienda Ospedaliero-Universitaria di Parma, Parma
³U.O. Diagnostica Ematochimica, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero-Universitaria di Parma, Italy

Abstract

ABSTRACT

Patients undergoing chronic hemodialysis have a high risk of arterial thrombotic events as well as vascular access thrombosis (VAT). The latter complication has been consistently associated with inherited (i.e., the prothrombin 20210 polymorphism, and polymorphisms in the genes encoding for transforming growth factor-β1, nitric oxide synthase, plasminogen activator inhibitor-1, angiotensin converting enzyme, and methylene tetrahydrofolate reductase), and acquired thrombotic risk factors (i.e., diabetes, obesity, atrial fibrillation, hypertension, hyperhomocysteinemia, hyperlipoproteinemia(a), low serum albumin, antiphospholipid antibodies, autoantibodies against protein C and S, erythropoietin administration, malnutrition, and cytomegalovirus infection). The three main factors involved in the pathogenesis of VAT overlap those of venous thrombosis and therefore include endothelial cell injury, blood stasis, and hypercoagulability. These changes are characteristic of patients affected by end-stage renal disease and might be further aggravated during and after hemodialysis. The aim of this review is to describe the epidemiology and pathogenesis of thrombosis of dialysis vascular access and to discuss the application of therapeutic interventions in prevention and treatment of this clinical problem.

KEYWORDS

Hemodialysis - thrombotic events - arteriovenous fistula - stenosis - vascular access thrombosis

Volltext

Referenzen

REFERENCES

1 Lindner A, Charra B, Sherrard D J, Scribner B H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974; 290 (13) 697-701
2 Winkelmayer W C. Tackling the Achilles' heel of hemodialysis. N Engl J Med. 2011; 364 (4) 372-374
3 Swartz R D, Messana J M, Boyer C J, Lunde N M, Weitzel W F, Hartman T L. Successful use of cuffed central venous hemodialysis catheters inserted percutaneously. J Am Soc Nephrol. 1994; 4 (9) 1719-1725
4 Trerotola S O, Johnson M S, Harris V J et al.. Outcome of tunneled hemodialysis catheters placed via the right internal jugular vein by interventional radiologists. Radiology. 1997; 203 (2) 489-495
5 Li L, Terry C M, Shiu Y T, Cheung A K. Neointimal hyperplasia associated with synthetic hemodialysis grafts. Kidney Int. 2008; 74 (10) 1247-1261
6 Akoh J A. Prosthetic arteriovenous grafts for hemodialysis. J Vasc Access. 2009; 10 (3) 137-147
7 Murad M H, Elamin M B, Sidawy A N et al.. Autogenous versus prosthetic vascular access for hemodialysis: a systematic review and meta-analysis. J Vasc Surg. 2008; 48 (5, Suppl) 34S-47S
8 National Kidney Foundation-Dialysis Outcomes Quality Initiative . NKF-DOQI clinical practice guidelines for vascular access. Am J Kidney Dis. 1997; 30 (4, Suppl 3) S150-S191
9 Papanikolaou V, Papagiannis A, Vrochides D et al.. The natural history of vascular access for hemodialysis: a single center study of 2,422 patients. Surgery. 2009; 145 (3) 272-279
10 Huber T S, Carter J W, Carter R L, Seeger J M. Patency of autogenous and polytetrafluoroethylene upper extremity arteriovenous hemodialysis accesses: a systematic review. J Vasc Surg. 2003; 38 (5) 1005-1011
11 Gibson K D, Gillen D L, Caps M T, Kohler T R, Sherrard D J, Stehman-Breen C O. Vascular access survival and incidence of revisions: a comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System Dialysis Morbidity and Mortality Study. J Vasc Surg. 2001; 34 (4) 694-700
12 Gilpin V, Nichols W K. Vascular access for hemodialysis: thrills and thrombosis. J Vasc Nurs. 2010; 28 (2) 78-83
13 Kherlakian G M, Roedersheimer L R, Arbaugh J J, Newmark K J, King L R. Comparison of autogenous fistula versus expanded polytetrafluoroethylene graft fistula for angioaccess in hemodialysis. Am J Surg. 1986; 152 (2) 238-243
14 Tordoir J H, Herman J M, Kwan T S, Diderich P M. Long-term follow-up of the polytetrafluoroethylene (PTFE) prosthesis as an arteriovenous fistula for haemodialysis. Eur J Vasc Surg. 1988; 2 (1) 3-7
15 Ascher E, Gade P, Hingorani A et al.. Changes in the practice of angioaccess surgery: impact of dialysis outcome and quality initiative recommendations. J Vasc Surg. 2000; 31 (1 Pt 1) 84-92
16 Ponikvar R, Buturović-Ponikvar J. Temporary hemodialysis catheters as a long-term vascular access in chronic hemodialysis patients. Ther Apher Dial. 2005; 9 (3) 250-253
17 Blankestijn P. Cuffed tunneled catheters for long-term vascular access. In: Conlon P J, Nicholson M, Schwab S, eds. Hemodialysis Vascular Access: Practice and Problems. New York: Oxford University; 2004: 67-84
18 Moureau N, Poole S, Murdock M A, Gray S M, Semba C P. Central venous catheters in home infusion care: outcomes analysis in 50,470 patients. J Vasc Interv Radiol. 2002; 13 (10) 1009-1016
19 Agarwal A K. Central vein stenosis: current concepts. Adv Chronic Kidney Dis. 2009; 16 (5) 360-370
20 Agarwal A K, Patel B M, Haddad N J. Central vein stenosis: a nephrologist's perspective. Semin Dial. 2007; 20 (1) 53-62
21 Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost. 2008; 34 (8) 747-761
22 Lippi G, Franchini M, Favaloro E J. Unsuspected triggers of venous thromboembolism—trivial or not so trivial?. Semin Thromb Hemost. 2009; 35 (7) 597-604
23 Montagnana M, Favaloro E J, Franchini M, Guidi G C, Lippi G. The role of ethnicity, age and gender in venous thromboembolism. J Thromb Thrombolysis. 2010; 29 (4) 489-496
24 Casserly L F, Dember L M. Thrombosis in end-stage renal disease. Semin Dial. 2003; 16 (3) 245-256
25 Paulson W D. Prediction of hemodialysis synthetic graft thrombosis: can we identify factors that impair validity of the dysfunction hypothesis?. Am J Kidney Dis. 2000; 35 (5) 973-975
26 Brophy D F, Bukaveckas B L, Ferreira-Gonzalez A, Archer K J, Martin E J, Gehr T W. A pilot study of genetic polymorphisms and hemodialysis vascular access thrombosis. Hemodial Int. 2009; 13 (1) 19-26
27 Knoll G A, Wells P S, Young D et al.. Thrombophilia and the risk for hemodialysis vascular access thrombosis. J Am Soc Nephrol. 2005; 16 (4) 1108-1114
28 Ataç B, Yakupoğlu U, Ozbek N, Ozdemir F N, Bilgin N. Role of genetic mutations in vascular access thrombosis among hemodialysis patients waiting for renal transplantation. Transplant Proc. 2002; 34 (6) 2030-2032
29 Bremer C, Schaefer R M. Heterozygosity for factor V Leiden in a haemodialysis patient with recurrent shunt thrombosis. Nephrol Dial Transplant. 1997; 12 (8) 1775-1776
30 Rios D R, Fernandes A P, Carvalho M G et al.. Hemodialysis vascular access thrombosis: The role of factor V Leiden, prothrombin gene mutation and ABO blood groups. Clin Chim Acta. 2011; 412 (5-6) 425-429
31 Födinger M, Mannhalter C, Pabinger I et al.. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients. Nephrol Dial Transplant. 1996; 11 (4) 668-672
32 Fekih-Mrissa N, Klai S, Bafoun A, Nciri B, Hmida J, Gritli N. Role of thrombophilia in vascular access thrombosis among chronic hemodialysis patients in Tunisia. Ther Apher Dial. 2011; 15 (1) 40-43
33 Heine G H, Ulrich C, Sester U, Sester M, Köhler H, Girndt M. Transforming growth factor beta1 genotype polymorphisms determine AV fistula patency in hemodialysis patients. Kidney Int. 2003; 64 (3) 1101-1107
34 Girndt M, Heine G H, Ulrich C, Köhler H. DialGene Consortium . Gene polymorphism association studies in dialysis: vascular access. Semin Dial. 2007; 20 (1) 63-67
35 Stracke S, Konner K, Köstlin I et al.. Increased expression of TGF-beta1 and IGF-I in inflammatory stenotic lesions of hemodialysis fistulas. Kidney Int. 2002; 61 (3) 1011-1019
36 Lazo-Langner A, Knoll G A, Wells P S, Carson N, Rodger M A. The risk of dialysis access thrombosis is related to the transforming growth factor-beta1 production haplotype and is modified by polymorphisms in the plasminogen activator inhibitor-type 1 gene. Blood. 2006; 108 (13) 4052-4058
37 Sung S A, Ko G J, Jo S K, Cho W Y, Kim H K, Lee S Y. Interleukin-10 and tumor necrosis factor-alpha polymorphisms in vascular access failure in patients on hemodialysis: preliminary data in Korea. J Korean Med Sci. 2008; 23 (1) 89-93
38 Basaran O, Atac F B, Karakayali F et al.. Endothelial nitric oxide synthase gene intron 4 (VNTR) polymorphism and vascular access graft thrombosis. J Invest Surg. 2007; 20 (1) 49-53
39 Trimarchi H, Duboscq C, Genoud V et al.. Plasminogen activator inhibitor-1 activity and 4G/5G polymorphism in hemodialysis. J Vasc Access. 2008; 9 (2) 142-147
40 Güngör Y, Kayataş M, Yıldız G, Özdemir Ö, Candan F. The presence of PAI-1 4G/5G and ACE DD genotypes increases the risk of early-stage AVF thrombosis in hemodialysis patients. Ren Fail. 2011; 33 (2) 169-175
41 Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990; 86 (4) 1343-1346
42 Sajgure A, Choudhury A, Ahmed Z, Choudhury D. Angiotensin converting enzyme inhibitors maintain polytetrafluroethylene graft patency. Nephrol Dial Transplant. 2007; 22 (5) 1390-1398
43 Heine G H, Ulrich C, Köhler H, Girndt M. Is AV fistula patency associated with angiotensin-converting enzyme (ACE) polymorphism and ACE inhibitor intake?. Am J Nephrol. 2004; 24 (4) 461-468
44 Molino D, De Lucia D, Marotta R et al.. In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis. Kidney Int. 2005; 68 (3) 1223-1229
45 Windus D W, Jendrisak M D, Delmez J A. Prosthetic fistula survival and complications in hemodialysis patients: effects of diabetes and age. Am J Kidney Dis. 1992; 19 (5) 448-452
46 Chou C Y, Chen J Y, Liu J H et al.. Atrial fibrillation linked to vascular access thrombosis in chronic hemodialysis patients. J Atheroscler Thromb. 2011; 18 (6) 448-453
47 Erkut B, Unlü Y, Ceviz M et al.. Primary arteriovenous fistulas in the forearm for hemodialysis: effect of miscellaneous factors in fistula patency. Ren Fail. 2006; 28 (4) 275-281
48 Obialo C I, Robinson T, Brathwaite M. Hemodialysis vascular access: variable thrombus-free survival in three subpopulations of black patients. Am J Kidney Dis. 1998; 31 (2) 250-256
49 Moustapha A, Naso A, Nahlawi M et al.. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation. 1998; 97 (2) 138-141
50 Fermo I, Vigano' D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med. 1995; 123 (10) 747-753
51 Zoccali C, Mallamaci F, Tripepi G. It is important to lower homocysteine in dialysis patients. Semin Dial. 2007; 20 (6) 530-533
52 Mallamaci F, Bonanno G, Seminara G et al.. Hyperhomocysteinemia and arteriovenous fistula thrombosis in hemodialysis patients. Am J Kidney Dis. 2005; 45 (4) 702-707
53 Churchill D N, Taylor D W, Cook R J et al.. Canadian hemodialysis morbidity study. Am J Kidney Dis. 1992; 19 (3) 214-234
54 Molino D, De Santo N G, Marotta R, Anastasio P, Mosavat M, De Lucia D. Plasma levels of plasminogen activator inhibitor type 1, factor VIII, prothrombin activation fragment 1 + 2, anticardiolipin, and antiprothrombin antibodies are risk factors for thrombosis in hemodialysis patients. Semin Nephrol. 2004; 24 (5) 495-501
55 Goldwasser P, Michel M A, Collier J et al.. Prealbumin and lipoprotein(a) in hemodialysis: relationships with patient and vascular access survival. Am J Kidney Dis. 1993; 22 (1) 215-225
56 Chou C Y, Kuo H L, Yung Y F, Liu Y L, Huang C C. C-reactive protein predicts vascular access thrombosis in hemodialysis patients. Blood Purif. 2006; 24 (4) 342-346
57 Muirhead N, Laupacis A, Wong C. Erythropoietin for anemia in hemodialysis patients: Results of a maintenance study. Nephrol Dial Transplant. 1992; 7 811-816
58 al-Momen A K, Huraib S O, Gader A M, Sulaimani F. Low dose danazol is effective in management of erythropoietin induced thrombosis. Thromb Res. 1991; 64 (5) 527-532
59 Lee Y K, Koo J R, Kim J K et al.. Effect of route of EPO administration on hemodialysis arteriovenous vascular access failure: a randomized controlled trial. Am J Kidney Dis. 2009; 53 (5) 815-822
60 Canadian Erythropoietin Study Group . Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990; 300 (6724) 573-578
61 Palmer S C, Navaneethan S D, Craig J C et al.. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010; 153 (1) 23-33
62 Tang I Y, Vrahnos D, Valaitis D, Lau A H. Vascular access thrombosis during recombinant human erythropoietin therapy. ASAIO J. 1992; 38 (3) M528-M531
63 Standage B A, Schuman E S, Ackerman D, Gross G F, Ragsdale J W. Does the use of erythropoietin in hemodialysis patients increase dialysis graft thrombosis rates?. Am J Surg. 1993; 165 (5) 650-654
64 Brunet P, Aillaud M F, San Marco M et al.. Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. Kidney Int. 1995; 48 (3) 794-800
65 Prakash R, Miller III C C, Suki W N. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis. 1995; 26 (2) 347-352
66 Prieto L N, Suki W N. Frequent hemodialysis graft thrombosis: association with antiphospholipid antibodies. Am J Kidney Dis. 1994; 23 (4) 587-590
67 Shalhoub R J. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet. 1974; 2 (7880) 556-560
68 Gültekin F, Alagözlü H, Candan F, Nadir I, Bakici M Z, Sezer H. The relationship between anticardiolipin antibodies and vascular access occlusion in patients on hemodialysis. ASAIO J. 2005; 51 (2) 162-164
69 Chuang F R, Chen T C, Yang C C et al.. IgM-anticardiolipin antibody and vascular access thrombosis in chronic hemodialysis patients. Ren Fail. 2005; 27 (1) 25-30
70 Weisinger J R, Kempson R L, Eldridge F L, Swenson R S. The nephrotic syndrome: a complication of massive obesity. Ann Intern Med. 1974; 81 (4) 440-447
71 Cull J D, Cull D L, Taylor S M et al.. Prosthetic thigh arteriovenous access: outcome with SVS/AAVS reporting standards. J Vasc Surg. 2004; 39 (2) 381-386
72 Gagliardi G M, Rossi S, Condino F et al.. Malnutrition, infection and arteriovenous fistula failure: is there a link?. J Vasc Access. 2011; 12 (1) 57-62
73 Lin C C, Yang W C. Prognostic factors influencing the patency of hemodialysis vascular access: literature review and novel therapeutic modality by far infrared therapy. J Chin Med Assoc. 2009; 72 (3) 109-116
74 Himmelfarb J, Stenvinkel P, Ikizler T A, Hakim R M. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002; 62 (5) 1524-1538
75 Malyszko J. Mechanism of endothelial dysfunction in chronic kidney disease. Clin Chim Acta. 2010; 411 (19-20) 1412-1420
76 Roy-Chaudhury P, Kelly B S, Miller M A et al.. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int. 2001; 59 (6) 2325-2334
77 Weiss M F, Scivittaro V, Anderson J M. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis. 2001; 37 (5) 970-980
78 Swedberg S H, Brown B G, Sigley R, Wight T N, Gordon D, Nicholls S C. Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation. 1989; 80 (6) 1726-1736
79 Reddy M K, Vasir J K, Hegde G V, Joshi S S, Labhasetwar V. Erythropoietin induces excessive neointima formation: a study in a rat carotid artery model of vascular injury. J Cardiovasc Pharmacol Ther. 2007; 12 (3) 237-247
80 Douzdjian V, Abecassis M M. A new technique of prosthetic arteriovenous fistula construction that eliminates the need for temporary access. Am J Surg. 1993; 166 (3) 304-305
81 Barth C, Boer W, Garzoni D et al.. Characteristics of hypotension-prone haemodialysis patients: is there a critical relative blood volume?. Nephrol Dial Transplant. 2003; 18 (7) 1353-1360
82 Kao C L, Chang J P. Fully ringed polytetrafluoroethylene graft for vascular access in hemodialysis. Asian Cardiovasc Thorac Ann. 2003; 11 (2) 171-173
83 Miller P E, Carlton D, Deierhoi M H, Redden D T, Allon M. Natural history of arteriovenous grafts in hemodialysis patients. Am J Kidney Dis. 2000; 36 (1) 68-74
84 Nampoory M R, Das K C, Johny K V et al.. Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplantation. Am J Kidney Dis. 2003; 42 (4) 797-805
85 Ambühl P M, Wüthrich R P, Korte W, Schmid L, Krapf R. Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation. Nephrol Dial Transplant. 1997; 12 (11) 2355-2364
86 Milburn J A, Cassar K, Ford I, Fluck N, Brittenden J. Prothrombotic changes in platelet, endothelial and coagulation function following hemodialysis. Int J Artif Organs. 2011; 34 (3) 280-287
87 Schoorl M, Schoorl M, Nubé M J, Bartels P C. Platelet depletion, platelet activation and coagulation during treatment with hemodialysis. Scand J Clin Lab Invest. 2011; 71 (3) 240-247
88 Mercier E, Branger B, Vecina F et al.. Tissue factor coagulation pathway and blood cells activation state in renal insufficiency. Hematol J. 2001; 2 (1) 18-25
89 Spijker H T, Graaff R, Boonstra P W, Busscher H J, van Oeveren W. On the influence of flow conditions and wettability on blood material interactions. Biomaterials. 2003; 24 (26) 4717-4727
90 Jurk K, Kehrel B E. Platelets: physiology and biochemistry. Semin Thromb Hemost. 2005; 31 (4) 381-392
91 Flaumenhaft R, Mairuhu A T, Italiano J E. Platelet- and megakaryocyte-derived microparticles. Semin Thromb Hemost. 2010; 36 (8) 881-887
92 Ando M, Iwata A, Ozeki Y, Tsuchiya K, Akiba T, Nihei H. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int. 2002; 62 (5) 1757-1763
93 Cianciolo G, Stefoni S, Donati G et al.. Intra- and post-dialytic platelet activation and PDGF-AB release: cellulose diacetate vs polysulfone membranes. Nephrol Dial Transplant. 2001; 16 (6) 1222-1229
94 Gritters-van den Oever M, Schoorl M, Schoorl M, Bartels P C, Grooteman M P, Nubé M J. The role of the extracorporeal circuit in the trapping and degranulation of platelets. Blood Purif. 2009; 28 (3) 253-259
95 Schoorl M, Schoorl M, Bartels P C. Changes in platelet volume, morphology and RNA content in subjects treated with haemodialysis. Scand J Clin Lab Invest. 2008; 68 (4) 335-342
96 Itoh S, Takeshita K, Susuki C, Shige-Eda K, Tsuji T. Redistribution of P-selectin ligands on neutrophil cell membranes and the formation of platelet-neutrophil complex induced by hemodialysis membranes. Biomaterials. 2008; 29 (21) 3084-3090
97 Sirolli V, Ballone E, Di Stante S, Amoroso L, Bonomini M. Cell activation and cellular-cellular interactions during hemodialysis: effect of dialyzer membrane. Int J Artif Organs. 2002; 25 (6) 529-537
98 Frank R D, Weber J, Dresbach H, Thelen H, Weiss C, Floege J. Role of contact system activation in hemodialyzer-induced thrombogenicity. Kidney Int. 2001; 60 (5) 1972-1981
99 Basmadjian D, Sefton M V, Baldwin S A. Coagulation on biomaterials in flowing blood: some theoretical considerations. Biomaterials. 1997; 18 (23) 1511-1522
100 Lucchi L, Ligabue G, Marietta M et al.. Activation of coagulation during hemodialysis: effect of blood lines alone and whole extracorporeal circuit. Artif Organs. 2006; 30 (2) 106-110
101 Kushiya F, Wada H, Sakakura M et al.. Atherosclerotic and hemostatic abnormalities in patients undergoing hemodialysis. Clin Appl Thromb Hemost. 2003; 9 (1) 53-60
102 Vaziri N D, Gonzales E C, Wang J, Said S. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis. Am J Kidney Dis. 1994; 23 (6) 828-835
103 Opatrný Jr K, Vít L, Opatrná S, Sulková S, Bodláková B. [Hypofibrinolysis after venous occlusion in patients treated with long-term hemodialysis]. Cas Lek Cesk. 1994; 133 (11) 346-349
104 Lottermoser K, Petras S, Pöge U et al.. The fibrinolytic system in chronic renal failure. Eur J Med Res. 2001; 6 (9) 372-376
105 De Marchi S, Falleti E, Giacomello R et al.. Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients. J Am Soc Nephrol. 1996; 7 (8) 1169-1177
106 Inoue A, Wada H, Takagi M et al.. Hemostatic abnormalities in patients with thrombotic complications on maintenance hemodialysis. Clin Appl Thromb Hemost. 2000; 6 (2) 100-103
107 Fan P Y, Schwab S J. Vascular access: concepts for the 1990s. J Am Soc Nephrol. 1992; 3 (1) 1-11
108 Young E W, Dykstra D M, Goodkin D A, Mapes D L, Wolfe R A, Held P J. Hemodialysis vascular access preferences and outcomes in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int. 2002; 61 (6) 2266-2271
109 Eleftheriadis T, Antoniadi G, Akritidou A et al.. A case report of recurrent vascular access thrombosis in a hemodialysis patient reveals combined acquired and inherited thrombophilia. Ther Apher Dial. 2008; 12 (2) 190-192
110 Sands J J. Vascular access 2007. Minerva Urol Nefrol. 2007; 59 (3) 237-249
111 Sands J J. Vascular access: the past, present and future. Blood Purif. 2009; 27 (1) 22-27

Martina MontagnanaM.D.

Sezione di Biochimica Clinica, Università degli Studi di Verona

Ospedale Policlinico G.B. Rossi, P.le Scuro 10, 37134 Verona, Italy

eMail: martina.montagnana@med.lu.se